Resource Type

Journal Article 311

Conference Videos 2

Year

2023 32

2022 27

2021 22

2020 25

2019 12

2018 24

2017 17

2016 7

2015 25

2014 14

2013 9

2012 6

2011 10

2010 12

2009 7

2008 15

2007 18

2006 5

2005 2

2004 3

open ︾

Keywords

chemotherapy 3

different 3

non-linear 3

China 2

File system 2

Gut microbiota 2

Non-volatile memory (NVM) 2

development 2

lymphoma 2

management 2

non-alcoholic fatty liver disease 2

non-point source pollution control 2

non-small cell lung cancer 2

prognosis 2

transformation 2

${\rm{NO}}_x $ removal 1

1

(DEM) 1

1) power model 1

open ︾

Search scope:

排序： Display mode:

Different sites of extranodal involvement may affect the survival of patients with relapsed or refractorynon-Hodgkin lymphoma after chimeric antigen receptor T cell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 786-791 doi: 10.1007/s11684-020-0751-3

Abstract: complete and durable remissions after anti-CD19 chimeric antigen receptor T (CAR-T) cell immunotherapy for relapsedor refractory non-Hodgkin lymphoma (r/r NHL) have not been well characterized.In a cohort of 32 treated patients, 12 (37.5%) and 8 (25%) patients exhibited soft tissue lymphoma and

Keywords： anti-CD19 chimeric antigen receptor T cell     soft tissue     bone marrow     relapsed or refractory non-Hodgkinlymphoma    

HTML PDF Collect

Primary spinal epidural non-Hodgkin’s lymphoma presented with spinal cord compression syndrome

Chunquan CAI MD, PhD, Qingjiang ZHANG BM, Changhong SHEN MD, PhD,

Frontiers of Medicine 2009, Volume 3, Issue 4,   Pages 499-502 doi: 10.1007/s11684-009-0075-9

Abstract: The spinal epidural space is an uncommon presenting site in primary non-Hodgkin’s lymphomas, especiallyA boy suffered spinal cord compression syndrome caused by primary spinal epidural non-Hodgkin’slymphoma.Histological examination revealed a non-Hodgkin’s B-cell lymphoma.Bone marrow aspiration was negative for lymphoma involvement.

Keywords： non-Hodgkin’     s lymphoma     primary     spinal cord compression syndrome     epidural space    

HTML PDF Collect

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 811-815 doi: 10.1007/s11684-020-0740-6

Abstract: Mantle cell lymphoma (MCL) is a distinct histological type of B-cell lymphoma with a poor prognosis.Several agents, such as proteasome inhibitors, immunomodulatory drugs, and inhibitors of B cell lymphoma-2 and Bruton’s tyrosine kinase have shown efficacy for relapsed or refractory (r/r) MCL but often haveChimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-Hodgkin’s lymphoma.

Keywords： anti-CD19 chimeric antigen receptor T cells     mantle cell lymphoma     relapsed or refractory     long-term follow-up    

HTML PDF Collect

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: second-generation anti-CD19 CAR bearing 4-1BB costimulatory molecule, for the treatment of patients with refractorydiffuse large B-cell lymphoma (DLBCL).Ten heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatmentTherefore, C-CAR011 is a safe and effective therapeutic option for Chinese patients with refractory DLBCL

Keywords： CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting    

HTML PDF Collect

Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report

Xinping Zhou, Juying Wei, Yinjun Lou, Gaixiang Xu, Min Yang, Hui Liu, Liping Mao, Hongyan Tong, Jie Jin

Frontiers of Medicine 2017, Volume 11, Issue 2,   Pages 287-292 doi: 10.1007/s11684-017-0510-2

Abstract:

Castleman disease (CD) is an uncommon non-clonal lymphoproliferative disorder with unknown etiologyNo standard therapy is recommended for relapsed/refractory CD patients, thus requiring development ofOur cohort of three adult patients with multicentric CD (MCD) were treated with refractory to traditionalPartial remission was achieved in first plasma-cell CD patient, who relapsed seven months after autologous

Keywords： Castleman disease     lenalidomide    

HTML PDF Collect

thyroid-stimulating hormone during radiotherapy to prevent primary hypothyroidism in medulloblastoma/PNET and Hodgkinlymphoma: a prospective cohort study

Maura Massimino, Marta Podda, Lorenza Gandola, Emanuele Pignoli, Ettore Seregni, Carlo Morosi, Filippo Spreafico, Andrea Ferrari, Emilia Pecori, Monica Terenziani

Frontiers of Medicine 2021, Volume 15, Issue 1,   Pages 101-107 doi: 10.1007/s11684-020-0752-2

Abstract: therefore the protective effect of suppressing TSH with L-thyroxine during RT for medulloblastoma/PNET and Hodgkinlymphoma (HL) in a prospective cohort study.

Keywords： iatrogenic primary hypothyroidism     late effects of radiotherapy     long-term follow-up     medulloblastoma     Hodgkinlymphoma    

HTML PDF Collect

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 766-772 doi: 10.1007/s11684-021-0916-8

Abstract: the efficacy and safety of anlotinib as third- or further-line therapy in patients with short-term relapsedPatients with short-term relapsed SCLC (disease progression within 3 months after completing ≥ two linesFor patients with short-term relapsed SCLC, third- or further-line anlotinib treatment was associated

Keywords： anlotinib     chemotherapy     short-term relapsed     small-cell lung cancer    

HTML PDF Collect

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 699-713 doi: 10.1007/s11684-022-0972-8

Abstract: cell therapy has achieved 40%–50% long-term complete response in relapsedor refractory diffuse large B-cell lymphoma (DLBCL) patients.microenvironments and reprogramming immune cell metabolism as effective therapeutic strategies to prevent lymphoma

Keywords： anti-CD19 chimeric antigen receptor T     immunotherapy     diffuse large B cell lymphoma     tumor microenvironment    

HTML PDF Collect

Analysis of the genomic landscape of primary central nervous system lymphoma using whole-genome sequencing

Frontiers of Medicine   Pages 889-906 doi: 10.1007/s11684-023-0994-x

Abstract: Primary central nervous system lymphoma (PCNSL) is an uncommon non-Hodgkin’s lymphoma with poor prognosis

Keywords： primary central nervous system lymphoma     whole-genome sequencing     TMSB4X     copy number variation    

HTML PDF Collect

Boron neutron capture therapy of gliomas and refractory pituitary adenomas: current status and future

Dai Congxin,Yao Yong,Wang Renzhi

Strategic Study of CAE 2012, Volume 14, Issue 8,   Pages 96-99

Abstract: Moreover, BNCT may have a significant therapeutic effect on refractory pituitary adenomas which haveThis paper reviews the current status of BNCT for human liomas and the possibility to treat refractory

Keywords： boron neutron capture therapy     gliomas     refractory pituitary adenomas    

HTML PDF Collect

Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed

Frontiers of Medicine 2021, Volume 15, Issue 5,   Pages 728-739 doi: 10.1007/s11684-021-0833-x

Abstract: However, little is known about the efficacy of HSCT2 in patients with relapsed/refractory acute leukemiaTherefore, we retrospectively analyzed the efficacy of HSCT2 in 28 patients with relapsed/refractoryOur findings suggest that HSCT2 could be a salvage option for patients with relapsed AL post-Chemo+m-DLI

Keywords： second hematopoietic stem cell transplantation     acute leukemia     relapse     chemotherapy     modified donor lymphocyte infusion    

HTML PDF Collect

Degradation of refractory organics in concentrated leachate by the Fenton process: Central composite

Senem Yazici Guvenc, Gamze Varank

Frontiers of Environmental Science & Engineering 2021, Volume 15, Issue 1, doi: 10.1007/s11783-020-1294-1

Abstract: Abstract • 90% total COD, 95.3% inert COD and 97.2% UV254 were removed. • High R2 values (over 95%) for all responses were obtained with CCD. • Operational cost was calculated to be 0.238 €/g CODremoved for total COD removal. • Fenton oxidation was highly-efficient method for inert COD removal. • BOD5/COD ratio of leachate concentrate raised from 0.04 to 0.4. The primary aim of this study is inert COD removal from leachate nanofiltration concentrate because of its high concentration of resistant organic pollutants. Within this framework, this study focuses on the treatability of leachate nanofiltration concentrate through Fenton oxidation and optimization of process parameters to reach the maximum pollutant removal by using response surface methodology (RSM). Initial pH, Fe2+ concentration, H2O2/Fe2+ molar ratio and oxidation time are selected as the independent variables, whereas total COD, color, inert COD and UV254 removal are selected as the responses. According to the ANOVA results, the R2 values of all responses are found to be over 95%. Under the optimum conditions determined by the model (pH: 3.99, Fe2+: 150 mmol/L, H2O2/Fe2+: 3.27 and oxidation time: 84.8 min), the maximum COD removal efficiency is determined as 91.4% by the model. The color, inert COD and UV254 removal efficiencies are determined to be 99.9%, 97.2% and 99.5%, respectively, by the model, whereas the total COD, color, inert COD and UV254 removal efficiencies are found respectively to be 90%, 96.5%, 95.3% and 97.2%, experimentally under the optimum operating conditions. The Fenton process improves the biodegradability of the leachate NF concentrate, increasing the BOD5/COD ratio from the value of 0.04 to the value of 0.4. The operational cost of the process is calculated to be 0.238 €/g CODremoved. The results indicate that the Fenton oxidation process is an efficient and economical technology in improvement of the biological degradability of leachate nanofiltration concentrate and in removal of resistant organic pollutants.

Keywords： Concentrated leachate     Fenton oxidation     Central composite design     Biodegradability     Inert COD    

HTML PDF Collect

Expression and bioinformatic analysis of lymphoma-associated novel gene KIAA0372

BAI Xiangyang, TANG Duozhuang, ZHU Tao, SUN Lishi, YAN Lingling, LU Yunping, ZHOU Jianfeng, MA Ding

Frontiers of Medicine 2007, Volume 1, Issue 1,   Pages 93-98 doi: 10.1007/s11684-007-0018-2

Abstract: The purpose of this study was to explore the differentially expressed genes in lymph-node cells (LNC) of lymphomas and reactive lymph node hyperplasia, and to perform an initial bioinformatic analysis on a novel gene, KIAA0372, which is highly expressed in the LNC of lymphomas. mRNA extracted from LNC of lymphomas and reactive lymph node hyperplasia were respectively marked with biotin and hybridized with Gene Expression Chips, resulting in differentially expressed genes. Initial bioinformatic analysis was then performed on a novel gene named KIAA0372, whose function has not yet been explored. Its structure and genomic location, its product s physical and chemical properties, subcellular localization and functional domains, were also predicted. Further, a systematic evolution analysis was performed on similar proteins from among several species. Using Gene Expression Chips, many differentially expressed genes were uncovered. Efficient bioinformatic analysis has fundamentally determined that KIAA0372 is an extracellular protein which may be involved in TGF-β signaling. Microarray is an efficient and high throughput strategy for detection of differentially expressed genes. And KIAA0372 is thought to be a potential target for tumor research using bioinformatic analysis.

Keywords： bioinformatic analysis     functional     KIAA0372     detection     Microarray    

HTML PDF Collect

Reevaluation of the effect of Dianxianning on seizure rate of refractory epilepsy as additive treatment

Liyun He, Tiancai Wen, Shiyan Yan, Runjin Li, Zufa Liu, Hui Ren, Jinmin Liu, Fengshan Zhang, Jianzhong Wu, Jian Liu

Frontiers of Medicine 2011, Volume 5, Issue 2,   Pages 229-234 doi: 10.1007/s11684-011-0139-5

Abstract: We observed the effect of Dianxianning, which was used as additive treatment to treat 206 epilepsy patients, on the epilepsy seizure rate. Based on a multicenter, prospective, randomized, and controlled clinical trial design, we used the seizure rate of epilepsy as the main index. For the treatment group comprising 137 patients, we combined Dianxianning with chemical medicine, which is the basic treatment. For the control group with 69 patients, we added placebo. The results showed that 1) Effect on seizure rate: After a three-month treatment, the seizure rate of the treatment group decreased by 37.84% on average, whereas that of the control group decreased by 13.18% on average. Statistically comparing the two groups, there was a significant difference between these groups ( <0.05). 2) Effect on seizure frequency: As time passed, the frequency in each group gradually decreased. After a three-month treatment, there was a significant difference between the two groups ( <0.05). 3) Comparison between the before and after treatment of each group: There was a very significant difference between the two groups ( <0.0001). The results indicated that, as an additive treatment, Dianxianning has a good effect on controlling the epilepsy seizure rate and frequency management. It is more effective than using chemical medicine alone.

Keywords： Dianxianning     epilepsy seizure     evaluation    

HTML PDF Collect

Autologous peripheral hematopoietic stem-cell transplantation in a patient with refractory pemphigus

SUN Ledong, SUN Jing, ZENG Kang, MENG Fanyi, DIAO Youtao, XU Dan, HUANG Liang, ZHAO Jie, Liu Qifa

Frontiers of Medicine 2008, Volume 2, Issue 2,   Pages 191-194 doi: 10.1007/s11684-008-0036-8

Abstract: effectiveness of autologous peripheral hematopoietic stem-cell transplantation in the treatment of refractorysuggests that autologous peripheral hematopoietic stem cell transplantation may be a potential “cure” for refractory

Keywords： serological activity     leukapheresis     peripheral hematopoietic     cyclophosphamide     resistance    

HTML PDF Collect

Title Author Date Type Operation

Different sites of extranodal involvement may affect the survival of patients with relapsed or refractorynon-Hodgkin lymphoma after chimeric antigen receptor T cell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Journal Article

Primary spinal epidural non-Hodgkin’s lymphoma presented with spinal cord compression syndrome

Chunquan CAI MD, PhD, Qingjiang ZHANG BM, Changhong SHEN MD, PhD,

Journal Article

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Journal Article

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Journal Article

Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report

Xinping Zhou, Juying Wei, Yinjun Lou, Gaixiang Xu, Min Yang, Hui Liu, Liping Mao, Hongyan Tong, Jie Jin

Journal Article

thyroid-stimulating hormone during radiotherapy to prevent primary hypothyroidism in medulloblastoma/PNET and Hodgkinlymphoma: a prospective cohort study

Maura Massimino, Marta Podda, Lorenza Gandola, Emanuele Pignoli, Ettore Seregni, Carlo Morosi, Filippo Spreafico, Andrea Ferrari, Emilia Pecori, Monica Terenziani

Journal Article

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup

Journal Article

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma

Journal Article

Analysis of the genomic landscape of primary central nervous system lymphoma using whole-genome sequencing

Journal Article

Boron neutron capture therapy of gliomas and refractory pituitary adenomas: current status and future

Dai Congxin,Yao Yong,Wang Renzhi

Journal Article

Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed

Journal Article

Degradation of refractory organics in concentrated leachate by the Fenton process: Central composite

Senem Yazici Guvenc, Gamze Varank

Journal Article

Expression and bioinformatic analysis of lymphoma-associated novel gene KIAA0372

BAI Xiangyang, TANG Duozhuang, ZHU Tao, SUN Lishi, YAN Lingling, LU Yunping, ZHOU Jianfeng, MA Ding

Journal Article

Reevaluation of the effect of Dianxianning on seizure rate of refractory epilepsy as additive treatment

Liyun He, Tiancai Wen, Shiyan Yan, Runjin Li, Zufa Liu, Hui Ren, Jinmin Liu, Fengshan Zhang, Jianzhong Wu, Jian Liu

Journal Article

Autologous peripheral hematopoietic stem-cell transplantation in a patient with refractory pemphigus

SUN Ledong, SUN Jing, ZENG Kang, MENG Fanyi, DIAO Youtao, XU Dan, HUANG Liang, ZHAO Jie, Liu Qifa

Journal Article